It eliminates cancer by targeting cluster of differentiation (CD)3ε, a surface antigen on normal cytotoxic T cells, and CD19, which is expressed on the surface of B-cell lymphoma, allowing patients’ own T cells to attack malignant B cells5. This evidence concerns the gene CD19 and cancer.